INTERNATIONAL PATENT: SINOTAU PHARMACEUTICAL GROUP, 北京先通国际医药科技股份有限公司 FILES APPLICATION FOR "USE OF 212PB-LABELED RADIOACTIVE COMPOUND IN PREPARATION OF DRUG FOR TREATING PROSTATE CANCER"

Posted On: 2025-04-19

GENEVA, April 19 -- SINOTAU PHARMACEUTICAL GROUP (1st-2nd Floor, Building1, No.5, Tongji Middle Road, Beijing Economic and Technological Development AreaDaxing District, Beijing 100176), 北京先通国际医药科技股份有限公司 (中国北京市大兴区北京经济技术开发区同济中路5号1幢1至2层) filed a patent application (PCT/CN2024/123846) for "USE OF 212PB-LABELED RADIOACTIVE COMPOUND IN PREPARATION OF DRUG FOR TREATING PROSTATE CANCER" on Oct 10, 2024. With publication no. WO/2025/077764, the details related to the...

Click here to read full article from source

To read the full article or to get the complete feed from this publication, please Contact Us.

Exclusive

Category

Source

Publication

Location

INTERNATIONAL PATENT: SINOTAU PHARMACEUTICAL GROUP, 北京先通国际医药科技股份有限公司 FILES APPLICATION FOR "USE OF 212PB-LABELED RADIOACTIVE COMPOUND IN PREPARATION OF DRUG FOR TREATING PROSTATE CANCER"